I. Functions and Features of the Platform
Yunnan Province Drug Purchasing Platform integrates the province's drug purchasing needs to form a scale effect, so as to centralize negotiation and purchasing with drug suppliers. The platform has the following functions and features:
1. Centralized Purchasing: The platform aggregates the drug purchasing demands of medical institutions at all levels across the province to form a unified purchase order, which realizes centralized purchasing and improves purchasing efficiency.
2. Openness and transparency: the platform adopts public bidding and competitive negotiation to conduct procurement, ensuring the openness, fairness and impartiality of the procurement process, and preventing the occurrence of corruption.
3. Optimized supply chain management: The platform establishes long-term and stable cooperative relationships with drug suppliers, optimizes supply chain management, and ensures stable quality and supply of drugs.
4. Reducing drug prices: Through centralized purchasing and negotiation, the platform helps to reduce the procurement cost of drugs, which in turn reduces drug prices and eases the burden on patients.
Second, the platform's operating process
The operating process of Yunnan Province's centralized drug procurement platform mainly includes the following steps:
1. Demand aggregation: medical institutions at all levels submit their drug procurement demands to the platform, which summarizes and analyzes the demands.
2. Bidding and Negotiation: Based on the summarized procurement demands, the platform issues bidding announcements or conducts competitive negotiations, and invites drug suppliers to participate in bidding or negotiation.
3. Evaluation and selection: The platform organizes experts to evaluate the bidding or negotiation results, and selects high-quality and low-priced drug suppliers for cooperation.
4. Contract signing and procurement: the platform signs procurement contracts with the selected drug suppliers and conducts drug procurement according to the contract.
5. Distribution and settlement: the drug suppliers deliver the drugs to the designated medical institutions in accordance with the contract, and the platform settles the payment with the suppliers.
Three, the platform significance and impact
Yunnan Province, the establishment and implementation of the centralized procurement of drugs platform, Yunnan Province, drug procurement and health care system has had a positive impact:
1. Reduce the price of medicines: through centralized purchasing and negotiation, the platform effectively reduces the cost of procurement of medicines, and thus reduces the price of medicines, so that the patients benefit.
2. Improving procurement efficiency: the platform has centralized and standardized the procurement process, improving procurement efficiency and reducing procurement costs.
3. Guaranteeing the demand for medicines: the platform can ensure that the demand for medicines of medical institutions is met and protect the rights and interests of patients in the use of medicines.
4. Promote the development of the pharmaceutical industry: the establishment of the platform helps to promote the healthy development of the pharmaceutical industry, optimize the industrial structure and improve the quality of drugs.
In summary:
Yunnan Province Drug Collection and Purchasing Platform has achieved the goals of lowering drug prices and improving purchasing efficiency by means of centralized purchasing, openness and transparency, and optimized supply chain management, which has had a positive impact on Yunnan Province's drug purchasing and healthcare system. The establishment of the platform helps to safeguard the medication needs of medical institutions, reduce the burden of medication on patients and promote the healthy development of the pharmaceutical industry.
Legal basis:
The Law of the People's Republic of China on the Administration of Pharmaceuticals
Article 5 stipulates:
The State encourages the research and creation of new medicines, and protects the lawful rights and interests of citizens, legal persons, and other organizations in the research and development of new medicines.
The People's Republic of China*** and the State Drug Administration Law
Article 26 stipulates:
Medical institutions purchasing drugs must establish and implement a system of incoming inspection and acceptance, and check the certificate of conformity of the drug and other markings; those that do not meet the prescribed requirements shall not be purchased and used.